Kurzfassung

A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients